PolyPid Ltd. (PYPD) is an Israeli clinical-stage biopharmaceutical company developing long-acting, locally delivered therapies. Its lead candidate, D-PLEX100, targets prevention of surgical site infections (SSIs) following abdominal colorectal surgery.
Four current analyst price targets were reviewed: H.C. Wainwright at $13 (Buy, November 12, 2026), Craig-Hallum at $12 (Buy, July 22, 2026), Oppenheimer at $10 (Outperform, initiated October 27, 2026), and Roth MKM at $8.50 (Buy, November 12, 2026). Their average is approximately $10.88, rounded to a central target of $11, with a wide low-to-high range of $8.50 to $13.
The spread reflects genuine disagreement. Bulls such as H.C. Wainwright weight the size of the addressable market and the Azurity partnership, while more cautious firms such as Roth MKM apply lower probability to regulatory and commercial execution. All four ratings are positive, but the roughly 53% gap between the lowest and highest target signals real uncertainty about a pre-revenue biotech. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
As of its most recent close, PYPD traded around $6.15, within a 52-week range of $3.50 to $7.15. Reaching $11 implies upside of about 79%, which is a very large move. The path depends primarily on binary regulatory events rather than steady earnings growth, because the company generates no meaningful revenue and posted a net loss of $7.8 million in the second quarter of 2026.
The nearest catalyst is the November 28, 2026 PDUFA (Prescription Drug User Fee Act) goal date for D-PLEX100, which was accepted for priority review. Approval would shift the debate to launch execution, while a delay or rejection would likely remove the central basis for current valuations. A U.S. launch is targeted for early 2027, with reimbursement clarity not expected until an NTAP decision in August 2027.
D-PLEX100 met its primary endpoint and a key secondary endpoint in the Phase 3 SHIELD II trial, showing a 60% relative risk reduction in SSI incidence. The FDA accepted the NDA (New Drug Application) with priority review, and a Marketing Authorization Application was validated by the European Medicines Agency in September 2026.
The July 2026 Azurity agreement provides $30 million in upfront and near-term payments, eligibility for more than $290 million in additional milestones, and tiered royalties in the mid-teens to mid-twenties percent range. Management believes current resources, including these payments, fund operations into 2028. Label expansion into broader abdominal surgery represents a meaningful optional opportunity beyond the initial indication.
The most immediate risk is regulatory: approval is not guaranteed, and the outcome of the FDA pre-approval manufacturing inspection has not been disclosed. A Complete Response Letter or approval delay could materially reset the stock.
Beyond approval, adoption is expected to be a gradual, account-by-account hospital formulary process. Pricing has not been disclosed and rests with Azurity, creating uncertainty around the economic case for hospitals. Reimbursement via NTAP, which could cover up to 75% of product cost, is not decided until August 2027. The company also remains deeply unprofitable, with cash of $6.6 million at mid-2026 before milestone receipts, and is highly concentrated on a single product.
PYPD has rallied sharply over the past year, climbing from a 52-week low near $3.50 toward a 52-week high of $7.15. The $7.00-to-$7.15 zone represents recent resistance that the stock must clear before a move toward double digits becomes a technical reality. A round-number area near $10-to-$11 sits well above any recent trading range and has no established support from current price action, underscoring how dependent the target is on positive news flow rather than chart structure.
Analyst price targets generally reflect a roughly 12-month research horizon, though firms do not always disclose a precise timeframe. The nearest items to watch are the November 28, 2026 PDUFA decision, any FDA pre-approval inspection updates, early 2027 launch execution and pricing disclosure, the August 2027 NTAP reimbursement decision, and the European Medicines Agency review expected in the second half of 2027. Quarterly earnings and cash runway commentary also remain important given the company's pre-revenue status.
In my research process, I often turn to Tickeron’s AI Daily Buy/Sell Signals for timely insights on volatile names like this. The tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from shifting market conditions, technical behavior, and AI-driven analysis. For a name like PYPD, where sentiment can turn quickly around a single regulatory headline, it helps discover opportunities, monitor existing positions, and spot changing trends more efficiently than manual screening alone.
Can PolyPid reach $11? The central $11 figure is the average of four recent analyst targets, not a forecast of what will happen. It sits roughly 79% above the current price, making it a demanding objective that hinges on FDA approval, a successful early 2027 launch, and continued execution by Azurity. The bullish case is grounded in positive Phase 3 data, priority review, and a validated commercial partner; the bear case points to binary regulatory risk, a gradual hospital adoption curve, unresolved pricing, and a single-product, pre-revenue profile. The wide $8.50-to-$13 analyst range captures that genuine uncertainty. Investors should treat the November 28 PDUFA decision as the pivotal near-term event, with launch execution and reimbursement timing shaping whether the stock can close even part of the gap toward double digits.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The Moving Average Convergence Divergence (MACD) for PYPD turned positive on October 22, 2026. Looking at past instances where PYPD's MACD turned positive, the stock continued to rise in 45 of 50 cases over the following month. The odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on PYPD as a result. In 104 of 128 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
PYPD moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PYPD crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +6.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where PYPD advanced for three days, in 179 of 218 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 103 of 115 cases where PYPD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The 10-day RSI Indicator for PYPD moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 18 similar instances where the indicator moved out of overbought territory. In 17 of the 18 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 49 cases where PYPD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PYPD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
PYPD broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. PYPD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (23.147) is normal, around the industry mean (3.592). P/E Ratio (-4.687) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PYPD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes
Industry Biotechnology